Emerging markets stock digest: Mikureed continues to rise, Sapeet hits the daily limit up.

<4883> Modalis 132 -14 consecutive declines. The Tokyo Stock Exchange has announced that it will increase the initial collateral rate for margin trading of the company's shares to 50% or more (including 20% or more cash) from the 1st, leading to selling pressure. Additionally, Japan Securities Finance has announced the implementation of increased collateral collection measures and will set the collateral rate for margin trading of the borrowing and lending transaction self-trading portion and the collateral trading of each non-netting participant to 50% (including 20% in cash collateral). <

Fisco JapanNov 1 02:26 ET

Symbio Pharmaceuticals---Progress as planned for 3Q financial estimates.

Shinbio Pharmaceuticals <4582> announced its consolidated financial results for the third quarter of the fiscal year ending December 2024 (January-September 24). Revenue decreased by 57.1% year-on-year to 1.898 billion yen, operating loss was 2.791 billion yen (compared to a loss of 0.283 billion yen in the same period last year), ordinary loss was 2.759 billion yen (compared to a loss of 0.156 billion yen), and quarterly net loss attributable to the parent company's shareholders was 2.845 billion yen (compared to a loss of 0.788 billion yen). Currently, Treaxisin (R) intravenous infusion solution 100mg/4mL [

Fisco JapanNov 1 00:36 ET

Hot stocks Digest (morning session): Mitsubishi Electric, Lasertec, Sociomex, etc.

Panasonic HD <6752>: 1366.5 yen (+128.5 yen) sharply rebounded. The company announced its second quarter financial results the day before, with an operating profit of 132.3 billion yen for the July-September period, an increase of 29.1% compared to the same period last year, significantly exceeding market financial estimates by nearly 25 billion yen. The full-year forecast remains at 380 billion yen, a 5.3% increase from the previous year, with a high possibility of downward revisions in the market, leading to a prevailing positive outlook. The expansion for AI data centers has driven growth in the energy business sector.

Fisco JapanOct 31 22:50 ET

SymBio Pharmaceuticals: Summary of Financial Results for the 3rd Quarter Ending 2024/12 [Japanese GAAP] (Consolidated)

JPXOct 31 02:30 ET · Announcements

SymBio Pharmaceuticals 9-Mos Loss Y2.85B Vs Loss Y788.00M

Dow JonesOct 31 02:30 ET

SymBio Pharmaceuticals Sees FY Loss Y3.63B

Dow JonesOct 31 02:30 ET